MyRisk
Germline hereditary-cancer panel; current documented configuration contains 63 clinically recommended genes and must not inherit analytical metrics from historical 25-gene validation.
- Developer
- Myriad Genetics
- Intended use
- Hereditary Cancer
- Cancer scope
- Breast cancer, Colorectal cancer, Kidney cancer, Lung cancer, Ovarian cancer, Pancreatic cancer, Prostate cancer, Skin cancer, Stomach cancer, Uterine cancer
- Specimen
- Whole blood
- Molecular modality
- DNA, RNA
- Current version
- Current MyRisk 63-gene configuration as of 2026-09
- Evidence context
- 1 structured studies · 0 indexed performance results · 3 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.